CN1198827C - 精选的K－252a衍生物 - Google Patents

精选的K－252a衍生物 Download PDF

Info

Publication number
CN1198827C
CN1198827C CNB97196985XA CN97196985A CN1198827C CN 1198827 C CN1198827 C CN 1198827C CN B97196985X A CNB97196985X A CN B97196985XA CN 97196985 A CN97196985 A CN 97196985A CN 1198827 C CN1198827 C CN 1198827C
Authority
CN
China
Prior art keywords
compound
lower alkyl
hydrogen
substituted
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB97196985XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1226893A (zh
Inventor
罗伯特·L·赫德金斯
约翰·P·马拉莫
滨野正见
田中玲子
村形力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Cephalon LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of CN1226893A publication Critical patent/CN1226893A/zh
Application granted granted Critical
Publication of CN1198827C publication Critical patent/CN1198827C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
CNB97196985XA 1996-06-03 1997-06-02 精选的K－252a衍生物 Expired - Fee Related CN1198827C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65736696A 1996-06-03 1996-06-03
US08/657,366 1996-06-03

Publications (2)

Publication Number Publication Date
CN1226893A CN1226893A (zh) 1999-08-25
CN1198827C true CN1198827C (zh) 2005-04-27

Family

ID=24636859

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB97196985XA Expired - Fee Related CN1198827C (zh) 1996-06-03 1997-06-02 精选的K－252a衍生物

Country Status (17)

Country Link
US (1) US6306849B1 (enExample)
EP (1) EP0918777B1 (enExample)
JP (1) JP2000511902A (enExample)
CN (1) CN1198827C (enExample)
AT (1) ATE222912T1 (enExample)
AU (1) AU716656B2 (enExample)
BR (1) BR9711093A (enExample)
CA (1) CA2256633C (enExample)
DE (1) DE69715010T2 (enExample)
DK (1) DK0918777T3 (enExample)
ES (1) ES2183184T3 (enExample)
NO (1) NO312464B1 (enExample)
NZ (2) NZ333018A (enExample)
PT (1) PT918777E (enExample)
RU (1) RU2205184C2 (enExample)
UA (1) UA67725C2 (enExample)
WO (1) WO1997046565A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
WO2000018407A1 (en) 1998-09-25 2000-04-06 Cephalon, Inc. Methods for preventing/treating damage to sensory hair cells and cochlear neurons
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
AR035971A1 (es) 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
WO2004016167A1 (en) * 2002-08-16 2004-02-26 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
EP1545615A4 (en) * 2002-10-04 2006-03-01 Rinat Neuroscience Corp METHODS OF TREATING CARDIAC ARRHYTHMIA AND PREVENTING DEATH OF CARDIAC ARRHYTHMIA USING NGF ANTAGONISTS
WO2004032870A2 (en) * 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
SI2270048T1 (sl) * 2002-12-24 2016-01-29 Rinat Neuroscience Corp. Protitelesa proti NGF-ju in postopki uporabe le-teh
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7655231B2 (en) * 2003-02-19 2010-02-02 Pfizer Inc. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
SG152226A1 (en) * 2004-04-07 2009-05-29 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
KR101431165B1 (ko) * 2008-12-22 2014-08-18 크레아빌리스 에스.에이. 인돌로카르바졸 화합물의 중합체 컨쥬케이트의 합성

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554402A (en) 1983-12-23 1985-11-19 Aluminum Company Of America Vibration damper for overhead conductor
JPS62120388A (ja) 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法
JPS62155284A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826037B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
EP0303697B1 (en) 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
JP2766360B2 (ja) 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
DE3835842A1 (de) * 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
WO1991009034A1 (en) 1989-12-14 1991-06-27 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
JPH0586068A (ja) 1991-03-04 1993-04-06 Rikagaku Kenkyusho 新規抗生物質ｒｋ−１４０９、その製造法並びに抗腫瘍剤及び抗炎症剤
CA2123096A1 (en) 1991-11-08 1993-05-13 Beat J. Knusel Compositions containing k-252 compounds for potentiation of neurotrophin activity
JP2593021B2 (ja) 1991-12-13 1997-03-19 伊藤ハム株式会社 ウシ胚の性の識別方法
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
ES2136103T3 (es) 1992-06-22 1999-11-16 Kyowa Hakko Kogyo Kk Procedimiento para la preparacion de derivados de estaurosporina.
JPH0673063A (ja) 1992-06-22 1994-03-15 Kyowa Hakko Kogyo Co Ltd Ｕｃｎ−０１誘導体
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
CA2123895A1 (en) * 1992-09-21 1994-03-31 Tatsuya Tamaoki A therapeutic agent for thrombocytopenia
DE69409641T2 (de) 1993-05-28 1998-11-26 Cephalon, Inc., West Chester, Pa. Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
WO1995000520A1 (en) 1993-06-17 1995-01-05 Ciba-Geigy Ag Indolocarbazole compound useful as proteinkinase c inhibitor
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

Also Published As

Publication number Publication date
BR9711093A (pt) 1999-08-17
ES2183184T3 (es) 2003-03-16
EP0918777A1 (en) 1999-06-02
DK0918777T3 (da) 2002-12-30
PT918777E (pt) 2003-01-31
NZ333018A (en) 2000-05-26
CA2256633A1 (en) 1997-12-11
JP2000511902A (ja) 2000-09-12
UA67725C2 (en) 2004-07-15
NO312464B1 (no) 2002-05-13
NO985622L (no) 1999-02-02
AU716656B2 (en) 2000-03-02
NO985622D0 (no) 1998-12-02
DE69715010D1 (de) 2002-10-02
HK1018703A1 (en) 1999-12-30
WO1997046565A1 (en) 1997-12-11
ATE222912T1 (de) 2002-09-15
CA2256633C (en) 2009-04-07
NZ504097A (en) 2005-06-24
RU2205184C2 (ru) 2003-05-27
AU3225397A (en) 1998-01-05
CN1226893A (zh) 1999-08-25
DE69715010T2 (de) 2003-04-03
EP0918777B1 (en) 2002-08-28
US6306849B1 (en) 2001-10-23

Similar Documents

Publication Publication Date Title
CN1198827C (zh) 精选的K－252a衍生物
CN100347185C (zh) 新的无环核苷膦酸酯衍生物,其盐及其制备方法
CN1310907C (zh) 杂环化合物和以其为有效成分的抗肿瘤药
CN1255392C (zh) 作为血管生成抑制剂的秋水仙醇衍生物
CN1040761C (zh) 含乙基膦酸酯侧链的稠合含氮杂环衍生物含有它们的药物组合物及其应用
CN1046725C (zh) 稠合的咪唑化合物,它们的制备和应用
CN1361100A (zh) 新的杂环衍生物及其医药用途
CN1646531A (zh) 作为髓过氧化物酶抑制剂的硫代黄嘌呤衍生物
HK1039615A1 (zh) 可用於治療脂血異常、動脉粥樣硬化和糖尿病的環狀化合物、藥物組合物和製備方法
CN1617854A (zh) 苯基(烷基)羧酸衍生物和二酸苯基烷基杂环衍生物及其用作具有血清葡萄糖和/或血清脂降低活性的药物的应用
CN1067053C (zh) 单环β－内酰胺类抗生素衍生物的中间体的制备方法
CN1511159A (zh) 氮基喜树碱衍生物
CN1918160A (zh) 用作趋化因子受体活性调节剂的新颖三环螺环衍生物
CN1231472C (zh) 嘧啶无环核苷衍生物、其制备方法及其用途
CN1055537A (zh) 3，5-双取代-2-异唑烷和异唑、其制备方法，含有该成分的制剂及其应用
CN1956982A (zh) 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
CN1112363A (zh) 制备5，8-二氢萘醌衍生物的方法，新的5，8-二氢萘醌衍生物和它们作为抗癌药的用途
CN86104787A (zh) 制备聚-4-氨基吡咯-2-甲酰胺基衍生物的方法
CN1867569A (zh) 作为抗癌剂的6－[(经取代的)苯基]三唑并嘧啶
CN1205704A (zh) 2,7－取代的八氢－吡咯并[1,2－a]吡嗪衍生物
CN1795179A (zh) 新的咪唑衍生物、其制备方法和其作为药物的用途
CN1671723A (zh) 新的偕二氟化化合物、其制备方法及其应用
CN1921867A (zh) 用于治疗hiv感染的膦酸核苷衍生物
CN1272340C (zh) 齐墩果酸偶联衍生物及其药物用途
CN1025617C (zh) 制备嘧啶衍生物及其医药上可用的盐的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050427

Termination date: 20120602